Tumor - Melanoma Brain Metastases: SRS and Dual Immunotherapy Outcomes After Prior Therapies

This episode delves into the clinical outcomes of treating melanoma brain metastases with stereotactic radiosurgery (SRS) in combination with ipilimumab and nivolumab. We examine findings from a study published in The Oncologist in 2026, utilizing the full text of the publication. The research retrospectively analyzed patients with melanoma brain metastases who had previously received either immune checkpoint inhibitors or targeted therapy. Key findings highlight treatment efficacy and potential toxicities in this challenging patient population. This discussion offers valuable insights for oncologists and radiation oncologists managing advanced melanoma. This information is for educational purposes and not a substitute for professional medical advice.